The Alliance for Longevity Initiatives (A4LI)

Happy International Longevity Month! 🧬 For A4LI, this month is a chance to celebrate the scientists, researchers, entrepreneurs, advocates, policymakers, and everyone else working to make longer, healthier lives a reality. Longevity science is moving quickly, and there is still a lot we don’t know. But every new discovery, clinical trial, policy conversation, and breakthrough brings us a little closer to understanding how we can extend not just lifespan, but healthspan. We are proud to be part of this growing community and excited for what’s ahead. Over the coming weeks, we will be connecting with the longevity community at events happening during Boston Longevity Week that starts today, and then hopping back to California Bay Area for our own longevity hike, Roundtable of Longevity Clinics, and Longevity Partnering Forum. Follow along for updates from the events, conversations, and people shaping the future of longevity. Boston Longevity Week: bostonlongevityweek.com/ A4LI Longevity Hike: luma.com/6yknf2vo Roundtable of Longevity Clinics: longevity-roundtable.com/ Longevity Partnering Forum: longevitypartnering.com/

Alzheimer’s disease can begin changing the brain years before symptoms appear. Understanding what drives those changes, and intervening earlier, could open new opportunities to prevent or delay cognitive decline. @ARPA_H is investing up to $48.8 million in new Alzheimer’s research focused on that early window. Mass General Brigham is launching a national clinical trial platform to test multiple preventive therapies simultaneously, before symptoms emerge. Washington University in St. Louis is building an open, AI-enabled data platform to help uncover the biological drivers of the disease. Other teams will investigate the earliest stages of cognitive decline and study how interventions affect brain health in at-risk older adults. These projects build on a broader ARPA-H Alzheimer’s research portfolio totaling up to $155.3 million. It includes BIOGAMI, which aims to detect and address early protein dysfunction, and NIGHT, which is studying ways to improve sleep and mitigate women’s elevated risk of Alzheimer’s. 📖 Read more here: arpa-h.gov/news-and-events/a… At A4LI, we believe advancing human health means addressing age-related diseases before they take hold. Research that uncovers the earliest drivers of Alzheimer’s could help shift the focus from managing disease to preventing or delaying its onset, giving more people the opportunity to live longer, healthier lives.

Women live longer than men on average, but those additional years are not always spent in good health. Closing that gap requires research that better accounts for women's biology and addresses the health challenges they face throughout life. The Women's Health Executive Order calls for more research into conditions ranging from cardiovascular disease and Alzheimer's to osteoporosis, menopause, and aging. It directs the NIH to establish a dedicated Women's Health Division within 90 days and creates a White House Women's Health Task Force to coordinate efforts across federal agencies, including @NIH, @FDA, @CMSGov, and @ARPA_H. 📖 Read the full Executive Order: whitehouse.gov/presidential-… At A4LI, we believe everyone should have the opportunity to live a longer, healthier life. Recognizing aging as a women's health priority is an important part of that goal. Continued investment in research and innovation can help ensure that longer lives also mean more years lived in good health.

Osteoarthritis affects tens of millions of Americans, and advanced cases can leave patients with few options beyond joint replacement. Current treatments can help manage pain and improve function, but regenerating lost cartilage and bone remains a major challenge. @ARPA_H's Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program is working to change that. Research teams at Duke University, the University of Colorado Boulder, Columbia University, and other institutions are developing experimental approaches ranging from targeted drug delivery to 3D-printed, living joint scaffolds. In animal studies, some approaches have shown promising signs of cartilage regeneration. The goal is to move these innovations toward human trials while developing treatments that could cost substantially less than current standards of care. 📖 Read more here: washingtonpost.com/wellness/… At A4LI, we're encouraged to see ARPA-H invest in research that could change how we treat age-related conditions. Maintaining joint health is essential to mobility and independence, and regenerative approaches could one day offer patients options beyond managing symptoms or replacing damaged joints. We'll be following NITRO as these experimental treatments advance toward clinical test.

Pancreatic ductal adenocarcinoma is one of the deadliest and most treatment-resistant cancers. It is most often diagnosed in older adults, frequently at a late stage when options are limited. @matterbio has received FDA clearance of its Investigational New Drug application for LM-LLO-TT, an immunotherapy built on a weakened form of the bacterium Listeria monocytogenes. It is designed to train the immune system to recognize and attack tumor cells. The clearance moves Matter Bio into the clinic with a first-in-human trial. The trial will test LM-LLO-TT alongside the chemotherapy gemcitabine in patients with unresectable pancreatic cancer, looking at safety, the right dose, and early signs of anti-tumor activity. 📖 Read more here: prnewswire.com/news-releases… At A4LI, we're proud to support partners like Matter Bio who are taking on some of the hardest problems in medicine. Cancer risk rises sharply with age, and new approaches to the toughest cancers are essential to helping people live longer, healthier lives. Congratulations to the Matter Bio team on this milestone. We look forward to following their progress as LM-LLO-TT enters clinical testing.

It’s the era of biobanking! Congrats to Cellino!!!

A4LI is proud to be a Community Partner for @foresightinst’s Vision Weekend USA 2026, taking place November 13–15 in San Francisco. Since 1992, Vision Weekend has brought together researchers, builders, and funders working at the forefront of science and technology. This year’s program explores longevity biotech, brain-computer interfaces, AI resilience, and more. Advances in aging science have the potential to transform human health, but translating scientific progress into real-world impact also requires thoughtful policy. Connecting the people driving innovation with those working to advance it is an important part of that process. We look forward to joining the conversation and connecting with others working to extend healthy human lifespan. Learn more and get your tickets: foresight.org/events/vision-…

📣 A4LI at the Medical Innovation Olympics This Friday, October 16, Jonathan Ross, A4LI’s Director of Administration & Operations, will join an expert panel on advancing healthspan extension through science, preventive care, and public policy. The discussion will explore how policy can support medical innovation, expand access to emerging therapies, and help shift healthcare toward preventing disease and extending healthy lives. Advancing policies that make this possible is central to A4LI’s mission. We looking forward to contributing to this important conversation. #MIO2026 #Longevity #Healthspan #HealthPolicy

Diseases like Alzheimer's, Parkinson's, and ALS can develop over many years, with protein misfolding and clumping contributing to damage in the brain and nervous system. By the time symptoms appear, significant damage may already have occurred. Understanding how these changes begin could open new opportunities to detect and treat disease earlier. @ARPA_H's new BIOGAMI program is tackling this challenge, investing up to $152 million over four years to understand how proteins become dysfunctional and develop ways to intervene. Six research teams, including those at the Buck Institute for Research on Aging, Johns Hopkins, MIT, and UC Berkeley, will combine protein science and computational tools to develop new approaches to early detection and treatment. While the initial focus is neurodegenerative disease, the findings could eventually have applications in cancer, diabetes, and other conditions. 📖 Read more here: arpa-h.gov/news-and-events/a… At A4LI, we're encouraged to see ARPA-H invest in understanding the underlying biology of disease. The earlier we can identify and address the processes that contribute to age-related conditions, the more opportunities researchers may have to change how these diseases are treated. We'll continue following BIOGAMI's progress and highlighting the work underway at ARPA-H to advance biomedical innovation.

An incredible milestone for the epigenetic reprogramming field. Congratulations to the team at Life Biosciences!!

Many chronic diseases share a common risk factor: the biology of aging itself. What if targeting that biology could help prevent or delay multiple diseases at once? The @NIH Geroscience Interest Group and the National Institute on Aging (NIA) will host the Fifth Geroscience Summit, Revisiting the Geroscience Hypothesis: Focus on Health, bringing together researchers, clinicians, and other stakeholders to advance the field and shape its research priorities for the next 3 to 5 years. Across two days, discussions will explore emerging areas of geroscience, approaches to measuring healthspan, and opportunities to accelerate the development of gerotherapeutics. 📍 Building 35, NIH Main Campus, Bethesda, MD (virtual attendance also available) 🗓️ December 2–3, 2026 ⏰ Dec. 2: 8:00 a.m.–4:45 p.m. ET | Dec. 3: 8:00 a.m.–5:00 p.m. ET 📖 Learn more and register here: nia.nih.gov/research/dab/wor… At A4LI, we believe targeting the underlying biology of aging could help prevent or delay multiple chronic diseases and transform how we approach human health. Turning that potential into better outcomes will require continued scientific progress alongside policies that accelerate therapeutic development and expand patient access. We look forward to seeing the geroscience community help shape what comes next for healthspan.

Some of the biggest challenges in human health require new ways of thinking. ARPA-H is looking for the scientists, engineers, physicians, and other technical experts with bold ideas for tackling problems that have remained out of reach through conventional approaches. Program Managers at ARPA-H have the opportunity to develop and lead ambitious programs, bring together multidisciplinary teams, and move transformative ideas toward real-world health outcomes. For those with the expertise and a vision for what could be possible, this is an opportunity to turn that vision into action.

Looking for a way to celebrate International Longevity Month this weekend? Join A4LI and Dr. @Barry_Breaux, Co-Founder of Longevity for the People, for a morning hike through Reinhardt Redwood Regional Park in Oakland this Saturday, October 10. Come get some movement, fresh air, and good conversation with others interested in building a longer, healthier future. Whether you're already part of the longevity community or simply looking for a reason to get outside, we'd love to see you there. 📍 Oakland, CA 🗓️ Saturday, October 10, 2026 RSVP here: luma.com/6yknf2vo Learn more about Longevity for the People: longevityforthepeople.org/

Bringing a new drug to patients typically takes more than a decade and costs around $2 billion, and about 90% of candidates fail along the way. Much of that time and cost comes from a rigid, phase-by-phase clinical trial process that has changed little in decades. @ARPA_H's new SURPASS program aims to change that. It uses digital twins, predictive modeling, and real-time data analysis so trials can adapt as evidence comes in, rather than waiting for each phase to finish. SURPASS launched alongside three other HHS efforts to expand clinical trial sites, build privacy-protected data infrastructure, and give patients a greater role in research. Together, these efforts could mean shorter timelines, lower costs, and fewer participants needed to reach clear answers. 📖 Read more here: arpa-h.gov/news-and-events/h… At A4LI, we are proud to see ARPA-H take on one of the biggest bottlenecks in modern medicine. The faster we can generate reliable evidence, the sooner promising therapies for age-related disease can reach the people who need them. We will keep advocating for a research and regulatory system built for the speed of today's science, and we look forward to following SURPASS as it moves forward.

Many cell-based therapies, including treatments for cancer and autoimmune disease, currently rely on storage at temperatures as low as -196°C. Maintaining that ultra-cold supply chain adds significant costs and can make these therapies harder to deliver where they are needed most. @ARPA_H’s new BioStabilization Systems (BoSS) program is taking on that challenge, investing up to $87 million to develop technologies that could keep life-saving cell therapies stable at room temperature. A 200-degree leap could mean more than eliminating freezers. It could help lower costs, simplify distribution, and make advanced therapies more accessible to patients and providers, including at community hospitals. 📖 Read more here: arpa-h.gov/news-and-events/a… At A4LI, we’re excited to see ARPA-H tackle the infrastructure challenges that can stand between scientific breakthroughs and the patients who need them. Innovations that make advanced therapies easier to manufacture, transport, store, and administer will be an important part of building a health system capable of delivering the next generation of medicine. As A4LI continues to advocate for policies that accelerate longevity and biomedical innovation, we look forward to highlighting more of the work underway at ARPA-H and across the biomedical research ecosystem.

We had an incredibly productive and memorable week on Capitol Hill advocating for A4LI policy proposals! There was strong alignment with our multi-disease therapeutic designation and the importance of @NIH. We’re excited to keep building on all these amazing conversations! @BernieSanders @ScottforFlorida @SenateAging @GOPHELP @RepPaulTonko @HouseCommerce @RepGuthrie